Molecular Devices (NASDAQ:MDCC)
Historical Stock Chart
From Jul 2019 to Jul 2024
Molecular Devices Introduces Two Assay Kits for Early ADME
Screening
SUNNYVALE, Calif., April 8 /PRNewswire-FirstCall/ -- Molecular Devices
Corporation (NASDAQ:MDCC) today announced the introduction of two new reagent
products for ADME assay screening-Transil(R) Membrane Affinity and Transil
Human Serum Albumin (HSA) Binding assay kits. The Transil assay kits provide
lead optimization and high-throughput screening laboratories with fast,
automatable, direct, biologically relevant solutions to increase the throughput
of ADME-related compound profiling.
The Transil Membrane Affinity assay provides data that correlates better to in
vivo studies compared to the more conventional water/octanol partitioning
assays because it uses beads which are coated with a lipid bilayer that mimic
interactions between compounds and cell membranes. The results are equivalent
to the liposome "gold standard" method, without the tedious preparation of
liposomes.
The Transil HSA Binding assay kit makes routine, high-throughput HSA binding
characterization easy because it contains beads which have been coated with
human serum albumin and pre-dispensed into a microplate format. The
pre-dispensed format increases throughput via parallel sample preparation and
assay reading on Molecular Devices' SpectraMax(R) microplate readers.
With the Transil assays, there is virtually no methods development required, as
each kit contains data analysis routines for processing high- throughput
screening of drug candidates for early ADME characterization. Furthermore, the
assays share nearly identical sample workup steps, so steps developed for one
assay are immediately applicable to the other.
Commenting on the launch, Christopher Silva, Director of Marketing for Life
Sciences Products at Molecular Devices stated, "The Transil assay kits enable
screening of compound libraries for membrane affinity and HSA binding for early
ADME properties which are not possible with current low-throughput methods.
These new assays require only one sample concentration, which simplifies
automation. Additionally, turnkey data analysis offers researchers compound
data within hours of synthesis or secondary screening. Because we have
integrated these assays with our SpectraMax(R) microplate reader line, we have
provided a more complete solution to our customers."
The kits are available in two formats for 96- or 384-well microplates. The
"high precision" version is ideal for profiling compounds at the lead
optimization stage of drug discovery; the "high throughput" version allows
characterization of compound libraries.
Molecular Devices Corporation is a leading supplier of high-performance
bioanalytical measurement systems that accelerate and improve drug discovery
and other life sciences research. The Company's systems and consumables enable
pharmaceutical and biotechnology companies to leverage advances in genomics,
proteomics and parallel chemistry to facilitate the high-throughput and
cost-effective identification and evaluation of drug candidates. The Company's
solutions are based on its advanced core technologies that integrate its
expertise in engineering, molecular and cell biology and chemistry. Molecular
Devices enables its customers to improve research productivity and
effectiveness, which ultimately accelerates the complex process of discovering
and developing new drugs.
This press release contains "forward-looking" statements, including statements
related to the prospects for or potential customer use of the Transil Membrane
Affinity and Transil Human Serum Albumin (HSA) Binding assay kits. Any
statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements. Words such as
"believes," "anticipates," "plans," "expects," "will," and similar expressions
are intended to identify forward-looking statements. There are a number of
important factors that could cause the results of Molecular Devices Corporation
to differ materially from those indicated by these forward-looking statements,
including, among others, risks related to the development of new products and
other risks detailed from time to time in the Company's SEC reports, including
its Annual Report on Form 10-K for the year ended December 31, 2004. Molecular
Devices Corporation does not undertake any obligation to update forward-looking
statements.
DATASOURCE: Molecular Devices Corporation
CONTACT: Tim Harkness of Molecular Devices Corporation,
+1-408-747-3533
Web site: http://www.moleculardevices.com/